Shopping Cart
Remove All
Your shopping cart is currently empty
Influenza HA (518-526)
(Synonyms: Influenza HA 518-526) Copy Product Info
🥰Excellent
Synonyms: Influenza HA 518-526
Catalog No. TP1517 Copy Product Info
🥰Excellent
Influenza HA (518-526) is an H-2d-restricted CD8+ T cell epitope derived from the influenza virus hemagglutinin. This sequence is highly conserved across multiple H5N1, some H9N2, and certain H1N1 strains. The epitope can bind to the mouse MHC class I allele Kd to form a complex, which is subsequently recognized by specific CD8+ T lymphocytes. In influenza-infected BALB/c mice, Influenza HA (518-526) represents an immunodominant epitope that stimulates CD8+ T cells to release IFN-γ, thereby inducing a robust immune response. Currently, this epitope has been widely applied in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza, among other fields.
Cas No. 186302-15-8
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 100 mg | Inquiry | Inquiry | Inquiry | |
| 500 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Influenza HA (518-526) is an H-2d-restricted CD8+ T cell epitope derived from the influenza virus hemagglutinin. This sequence is highly conserved across multiple H5N1, some H9N2, and certain H1N1 strains. The epitope can bind to the mouse MHC class I allele Kd to form a complex, which is subsequently recognized by specific CD8+ T lymphocytes. In influenza-infected BALB/c mice, Influenza HA (518-526) represents an immunodominant epitope that stimulates CD8+ T cells to release IFN-γ, thereby inducing a robust immune response. Currently, this epitope has been widely applied in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza, among other fields. |
| In vitro | Method: Influenza HA (518-526) was inserted into the stalk region of neuraminidase (NA) of PR8 influenza virus to construct a recombinant virus. NA enzyme activity was measured after virus purification. MDCK cells were infected at an MOI of 0.001, virus growth kinetics were assessed at 48 h post-infection, and plaque size was observed at 72 h post-infection. Result: After insertion of Influenza HA (518-526), the NA enzyme activity of the virus decreased to 15% of that of the wild-type virus . However, the virus growth kinetics (at 48 h) and plaque size (at 72 h) in MDCK cells showed no significant difference from those of the wild-type virus [1]. |
| In vivo | Method: BALB/c mice were intranasally inoculated with PR8/NA-HA₅₁₈₋₅₂₆ virus, and body weight changes were recorded daily to evaluate pathogenicity. Spleen cells were isolated 10-14 days post-infection and restimulated with Influenza HA (518-526) peptide, and CTL responses were detected by IFN-γ ELISPOT and flow cytometry. Result: After integration of Influenza HA (518-526) into the neuraminidase stalk of PR8 influenza virus, the pathogenicity of this recombinant virus in mice was weaker than that of the wild-type PR8 virus. It induced Influenza HA (518-526)-specific CTL responses but did not induce RSV F₈₅₋₉₃-specific CTL responses [1]. |
| Synonyms | Influenza HA 518-526 |
| Molecular Weight | 940.05 |
| Formula | C42H69N9O15 |
| Cas No. | 186302-15-8 |
| Smiles | [C@H](CC1=CC=C(O)C=C1)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC(C)C)C(O)=O)=O)CO)=O)CO)=O)C)=O)C(C)C)=O)[C@@H](C)O)=O)CO)=O)NC([C@H]([C@H](CC)C)N)=O |
| Relative Density. | 1.300 g/cm3 (Predicted) |
| Sequence | Ile-Tyr-Ser-Thr-Val-Ala-Ser-Ser-Leu |
| Sequence Short | IYSTVASSL |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Influenza HA (518-526) chemical structure | Influenza HA (518-526) in vivo | Influenza HA (518-526) in vitro | Influenza HA (518-526) formula | Influenza HA (518-526) molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.